In a full‑term infant with meconium aspiration syndrome and refractory hypoxemia despite optimal ventilation, surfactant, and inhaled nitric oxide (iNO), is sildenafil an effective adjunct for persistent pulmonary hypertension of the newborn (PPHN)?

Sildenafil as Adjunctive Therapy in Refractory PPHN

Sildenafil is a reasonable adjunctive therapy for this infant with meconium aspiration syndrome and persistent pulmonary hypertension refractory to inhaled nitric oxide, particularly when the oxygenation index exceeds 25.

Guideline-Based Recommendation

The 2015 AHA/ATS Pediatric Pulmonary Hypertension Guidelines provide clear direction for this clinical scenario. Sildenafil receives a Class IIa recommendation (reasonable adjunctive therapy) with Level of Evidence B for infants with PPHN who are refractory to iNO, especially with an oxygenation index >25 1. This represents the highest quality guideline evidence available and directly addresses your clinical question.

Treatment Algorithm for iNO-Refractory PPHN

When an infant fails to respond adequately to iNO (defined as <10 mmHg increase in PaO2 at 30 minutes), proceed as follows:

1. Optimize lung recruitment first - Ensure adequate ventilation strategies are maximized, as lung recruitment improves iNO efficacy in parenchymal lung disease like meconium aspiration 1

2. Calculate the oxygenation index: (mean airway pressure × FiO₂ × 100) / PaO₂

   • If OI >25: Sildenafil is reasonable as adjunctive therapy
   • If OI >40: Consider ECMO referral 1

3. Initiate sildenafil at 0.5-2 mg/kg/dose every 6 hours via oral/enteral route 2, 3, 4

4. Monitor for response within 6-10 hours: expect gradual improvement in oxygenation, decreased OI, and reduced pulmonary artery pressure 2

Evidence Supporting Sildenafil Use

While iNO remains the FDA-approved first-line pulmonary vasodilator for PPHN 5, approximately 30-40% of infants fail to achieve sustained improvement with iNO alone 1. The Cochrane systematic review (2017) demonstrated that sildenafil significantly reduces mortality compared to placebo (RR 0.20,95% CI 0.07-0.56; number needed to treat = 3) and improves oxygenation parameters 6. This evidence comes primarily from resource-limited settings where iNO was unavailable, but the physiologic rationale supports its use as adjunctive therapy.

Mechanism and Rationale

Sildenafil works through a complementary mechanism to iNO. Both increase cyclic GMP in pulmonary vascular smooth muscle, but via different pathways: iNO activates guanylate cyclase, while sildenafil inhibits phosphodiesterase-5 breakdown of cyclic GMP 1. This synergistic effect may explain why sildenafil can improve outcomes when added to iNO 2.

Critical Safety Considerations

Monitor mean arterial blood pressure closely - While systemic hypotension is a theoretical concern, recent evidence suggests that at appropriate doses (<3 mg/kg/day), sildenafil does not significantly decrease blood pressure in neonates with MAS or sepsis 4. However, systemic hypotension occurs more frequently with sildenafil than with inhaled therapies 3.

Avoid in suspected left ventricular dysfunction - The guidelines specifically note that pulmonary vasodilators should be used cautiously when LV dysfunction is present, as lowering pulmonary vascular resistance may worsen pulmonary venous hypertension 1. In such cases, milrinone (Class IIa recommendation) may be preferable as it provides both pulmonary vasodilation and inotropic support 1.

Alternative Considerations

If sildenafil is unavailable or contraindicated:

• Inhaled prostacyclin analogs (Class IIb recommendation) may be considered for OI >25 1
• Intravenous milrinone is reasonable if LV dysfunction is present 1

When to Escalate to ECMO

ECMO is indicated (Class I recommendation) for severe PH or hypoxemia refractory to iNO and optimization of respiratory/cardiac function 1. Specific triggers include:

• OI persistently >40 despite maximal medical therapy
• Inability to maintain adequate oxygenation despite sildenafil addition
• Progressive cardiovascular collapse

Important Caveats

The 2025 ATS guideline 7 discusses sildenafil primarily in the context of chronic pediatric pulmonary hypertension (particularly BPD-associated PH and Group 3 PH), noting it is "often successfully used" in these populations. However, this does not supersede the specific 2015 recommendations for acute PPHN management, which remain the most applicable guideline for your clinical scenario.

Consider evaluation for underlying disorders (alveolar capillary dysplasia, genetic surfactant protein diseases) if the infant fails to improve after 5 days of vasodilator therapy, as these conditions have poor prognosis and may not respond to standard therapies 1.